SYNTHESIS AND RECENT DEVELOPMENTS OF MESOPOROUS SILICA NANOPARTICLES IN TARGETED ANTI-TUMOR THERAPY
Main Article Content
Keywords
Mesoporous silica nanoparticles, sodium orthsilicate, Drug resistance, nanomedicine
Abstract
Current approaches to diagnosis and treatment have undergone a revolutionary shift as a result of recent developments in drug delivery technologies that make use of a range of carriers. Mesoporous silica nanoparticles have been developed as a result of the need for materials with high mechanical, chemical, and thermal properties (MSNs). Because of what sets these ordered porous materials apart from the rest, they have attracted a lot of interest as drug carriers. It is affordable since they may be produced through a somewhat easy procedure. Furthermore, the morphology, pore size and volume, and particle size can all be altered appropriately by adjusting the parameters during the synthesis. The last several years have seen a sharp rise in the amount of research on MSNs as drug carriers for the management of diverse diseases. Its broad use as a carrier for loading macromolecules like proteins, siRNA, and other macromolecules as well as tiny compounds has made it an adaptable tool. Researchers have recently made several changes to the MSN architecture to investigate its potential for use in antimicrobial therapy and drug-resistant chemotherapy. We have covered the synthesis of these multifunctional nanoparticles as well as the variables affecting the shape and size of this amazing carrier in this review. This review's second section focuses on the developments and applications of MSNs, particularly in the realm of biomedicine, to increase their potential applications. Additionally, we have discussed the gaps in our understanding of how it interacts with a biological system, which poses a significant obstacle to this carrier's advancement to the clinical stage. The last section of our examination covered a few of the most significant patents related to MSNs used for medicinal purposes.
References
2. Mudshinge S R, Deore AB, Patil S, Bhalgat C M. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm. J. 2011; 19:129–141.
3. Kankala R K, Zhang Y S, Wang S B, Lee C H, Chen A Z. Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications. Adv. Healthc. Mater. 2017; 6: 1700433.
4. Kankala R K, Zhu K, Sun X N, Liu C G, Wang S B, Chen A Z. Cardiac Tissue Engineering on the Nanoscale. ACS Biomater. Sci. Eng. 2018; 4:800–818.
5. Gong T, Xie J, Liao J, Zhang T, Lin S, Lin Y. Nanomaterials and bone regeneration. Bone Res. 2015; 3:15029.
6. Alhariri M, Azghani A, Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert Opin. Drug Deliv. 2013; 10:1515–1532.
7. Deshpande P P, Biswas S, Torchilin V P. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013; 8:1509–1528.
8. Puri A, Loomis K, Smith B, Lee J H, Yavlovich A, Heldman E. Blumenthal, R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit. Rev. Ther. Drug Carr. Syst. 2009; 26:523–580.
9. Gad A, Kydd J, Piel B, Rai P. Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy. Int. J. Nanomed. Nanosurg. 2016; 2.
10. Cheng C J, Tietjen G T, Saucier-Sawyer J K, Saltzman W M. A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 2015; 14:239–247.
11. Han Y H, Kankala R, Wang S B, Chen A Z. Leveraging Engineering of Indocyanine Green-Encapsulated Polymeric Nanocomposites for Biomedical Applications. Nanomaterials. 2018; 8: 360.
12. Pandita D, Poonia N, Kumar S, Lather V, Madaan K. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J. Pharm. Bioallied Sci. 2014; 6:139–150.
13. Hiemenz J W, Walsh T J. Lipid formulations of amphotericin B: Recent progress and future directions. Clin. Infect. Dis. 1996; 22 (Suppl. 2): S133–S144.
14. Kaposi’s sarcoma: DaunoXome approved. AIDS Treat. News. 1996; 3–4.
15. Barenholz Y. (Chezy) Doxil®—The first FDA-approved nano-drug: Lessons learned. J. Control. Release. 2012; 160:117–134.
16. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): A new approach in breast cancer therapy. Expert Opin. Pharm. 2002; 3:1739–1751.
17. Junghanns J U A H, Müller R H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 2008; 3:295–309.
18. Giner-Casares J J, Henriksen-Lacey M, Coronado-Puchau M, Liz-Marzán L M. Inorganic nanoparticles for biomedicine: Where materials scientists meet medical research. Mater. Today. 2016; 19:19–28.
19. Kankala R K, Tsai P Y, Kuthati Y, Wei P R, Liu C L, Lee C H. Overcoming multidrug resistance through co-delivery of ROS-generating nano-machinery in cancer therapeutics. J. Mater. Chem. B 2017; 5:1507–1517.
20. Kuthati Y, Kankala R K, Lee C H. Layered double hydroxide nanoparticles for biomedical applications: Current status and recent prospects. Appl. Clay Sci. 2015; 112–113:100–116.
21. Choi J, Burns A A, Williams R M, Zhou Z, Flesken-Nikitin A, Zipfel W R, Wiesner U, Nikitin A Y. Core-shell silica nanoparticles as fluorescent labels for nanomedicine. J. Biomed. Opt. 2007; 12:64007.
22. Burns A A, Vider J, Ow H, Herz E, Penate-Medina O, Baumgart M, Larson S M, Wiesner U, Bradbury M. Fluorescent Silica Nanoparticles with Efficient Urinary Excretion for Nanomedicine. Nano Lett. 2009; 9:442–448.
23. Slowing I I, Trewyn B G, Lin V S Y. Mesoporous Silica Nanoparticles for Intracellular Delivery of Membrane-Impermeable Proteins. J. Am. Chem. Soc. 2007; 129:8845–8849
24. Deodhar G V, Adams M L, Trewyn B G. Controlled release and intracellular protein delivery from mesoporous silica nanoparticles. Biotechnol. J. 2017; 12:1600408.
25. Cha W, Fan R, Miao Y, Zhou Y, Qin C, Shan X, Wan X, Li J. Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications. Molecules. 2017; 22:782.
26. Tao C, Zhu Y, Xu Y, Zhu M, Morita H, Hanagata N. Mesoporous silica nanoparticles for enhancing the delivery efficiency of immunostimulatory DNA drugs. Dalton Trans. 2014; 43:5142–5150.
27. Möller K, Müller K, Engelke H, Bräuchle C, Wagner E, Bein T. Highly efficient siRNA delivery from core–shell mesoporous silica nanoparticles with multifunctional polymer caps. Nanoscale. 2016; 8:4007–4019.
28. Hanafi-Bojd M Y, Ansari L, Malaekeh-Nikouei B. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles. Ther. Deliv. 2016; 7:649–655.
29. Riikonen J, Xu W, Lehto V P. Mesoporous systems for poorly soluble drugs—Recent trends. Int. J. Pharm. 2018; 536:178–186.
30. Maleki A, Kettiger H, Schoubben A, Rosenholm J M, Ambrogi V, Hamidi M. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs. J. Control. Release. 2017; 262:329–347.
31. Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed. Nanotechnol. Biol. Med. 2015; 11:313–327.
32. Mamaeva V, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine—Recent advances. Adv. Drug Deliv. Rev. 2013; 65:689–702.
33. Tao Z. Mesoporous silica-based nanodevices for biological applications. RSC Adv. 2014; 4:18961–18980.
34. Huo Q, Margolese D I, Stucky G D. Stucky Surfactant Control of Phases in the Synthesis of Mesoporous Silica-Based Materials. Chem. Mater. 1996; 8:1147–1160.
35. Beck J S, Vartuli J C, Roth W J, Leonowicz M E, Kresge C T, Schmitt K D, Chu C T W, Olson D H, Sheppard E W, McCullen S B et al. A new family of mesoporous molecular sieves prepared with liquid crystal templates. J. Am. Chem. Soc. 1992; 114:10834–10843.
36. Trewyn B G, Slowing I I, Giri S, Chen H T, Lin V S Y. Synthesis and Functionalization of a Mesoporous Silica Nanoparticle Based on the Sol–Gel Process and Applications in Controlled Release. Acc. Chem. Res. 2007; 40:846–853.
37. Oye G, Sjöblom J, Stöcker M. Synthesis, characterization and potential applications of new materials in the mesoporous range. Adv. Colloid Interface Sci. 2001; 89–90:439–466.
38. Zhao D, Huo Q, Feng J, Chmelka B F, Stucky G D. Nonionic Triblock and Star Diblock Copolymer and Oligomeric Surfactant Syntheses of Highly Ordered, Hydrothermally Stable, Mesoporous Silica Structures. J. Am. Chem. Soc. 1998; 120:6024–6036.
39. Tozuka Y, Wongmekiat A, Kimura K, Moribe K, Yamamura S, Yamamoto K. Effect of Pore Size of FSM-16 on the Entrapment of Flurbiprofen in Mesoporous Structures. Chem. Pharm. Bull. 2005; 53:974–977.
40. Nandiyanto A B D, Kim S G, Iskandar F, Okuyama K. Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters. Microporous Mesoporous Mater. 2009; 120:447–453.
41. Heikkilä T, Salonen J, Tuura J, Hamdy M S, Mul G, Kumar N, Salmi T, Murzin D Y, Laitinen L, Kaukonen A M et al. Mesoporous silica material TUD-1 as a drug delivery system. Int. J. Pharm. 2007; 331:133–138.
42. Kumar D, Schumacher K, von Hohenesche C D F, Grun M, Unger K K. MCM-41, MCM-48 and related mesoporous adsorbents: Their synthesis and characterisation. Colloids Surf. A Physicochem. Eng. Asp. 2001; 187–188:109–116.
43. Wang S. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mater. 2009; 117:1–9.
44. Wang S, Li H. Structure directed reversible adsorption of organic dye on mesoporous silica in aqueous solution. Microporous Mesoporous Mater. 2006; 97:21–26.
45. Ukmar T, Planinsek O. Ordered mesoporous silicates as matrices for controlled release of drugs. Acta Pharm. 2010; 60:373–385.
46. Zhao D, Zhou W, Wan Y. Ordered Mesoporous Materials; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2013; ISBN 3527647899.
47. Kim K S, Park M, Kim T W, Kim J E, Papoulis D, Komarneni S, Choi J. Adsorbate-dependent uptake behavior of topographically bi-functionalized ordered mesoporous silica materials. J. Porous Mater. 2015; 22:1297–1303.
48. Lu G Q, Zhao X S. Nanoporous Materials: Science and Engineering; Series on Chemical Engineering; Imperial College Press: London, UK; World Scientific Publishing Co. Singapore, 2004; (4):210-215.
49. Ge S, Geng W, He X, Zhao J, Zhou B, Duan L, Wu Y, Zhang Q. Effect of framework structure, pore size and surface modification on the adsorption performance of methylene blue and Cu2+ in mesoporous silica. Colloids Surf. A Physicochem. Eng. Asp. 2018; 539:154–162.
50. Mayoral A, Blanco R M, Diaz I. Location of enzyme in lipase-SBA-12 hybrid biocatalyst. J. Mol. Catal. B Enzym. 2013; 90:23–25.
51. Galarneau A, Cambon H, Di Renzo F, Ryoo R, Choi M, Fajula F. Microporosity and connections between pores in SBA-15 mesostructured silicas as a function of the temperature of synthesis. New J. Chem. 2003; 27:73–79.
52. Lercher J A, Kaliaguine S, Gobin O C. SBA-16 Materials Synthesis, Diffusion and Sorption Properties; Technical University of Munich: Munich, Germany. 2006.
53. Kleitz F, Liu D, Gopinathan M A, Park I S, Solovyov L A, Shmakov A N, Ryoo R. Large Cage Face-Centered-Cubic Fm3m Mesoporous Silica: Synthesis and Structure. J. Phys. Chem. B 2003; 107:14296–14300.
54. Kalbasi J R, Zirakbash A. Synthesis, characterization and drug release studies of poly(2-hydroxyethyl methacrylate)/KIT-5 nanocomposite as an innovative organic–inorganic hybrid carrier system. RSC Adv. 2015; 5:12463–12471.
55. Jammaer J, Aerts A, D’Haen J, Seo J W, Martens J A. Convenient synthesis of ordered mesoporous silica at room temperature and quasi-neutral pH. J. Mater. Chem. 2009; 19:8290–8293.
56. Vialpando M, Aerts A, Persoons J, Martens J, Van Den Mooter G. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: Influence of pressure on the structure and drug release. J. Pharm. Sci. 2011; 100:3411–3420.
57. Stober W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. J. Colloid Interface Sci. 1968; 26:62–69.
58. Grün M, Lauer I, Unger K K. The synthesis of micrometer- and submicrometer-size spheres of ordered mesoporous oxide MCM-41. Adv. Mater. 1997; 9:254–257.
59. Blin J L, Impéror-Clerc M. Mechanism of self-assembly in the synthesis of silica mesoporous materials: In situ studies by X-ray and neutron scattering. Chem. Soc. Rev. 2013; 42:4071–4082.
60. Gao C, Qiu H, Zeng W, Sakamoto Y, Terasaki O, Sakamoto K, Chen Q, Che S. Formation Mechanism of Anionic Surfactant-Templated Mesoporous Silica. Chem. Mater. 2006; 18:3904–3914.
61. Flodström K, Wennerström H, Alfredsson V. Mechanism of Mesoporous Silica Formation. A Time-Resolved NMR and TEM Study of Silica−Block Copolymer Aggregation. Langmuir. 2004; 20:680–688.
62. Attard G S, Glyde J C, Göltner C G. Liquid-crystalline phases as templates for the synthesis of mesoporous silica. Nature. 1995; 378:366–368.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Fatima Zahid
Ibadat International University (IIUI), Islamabad, Pakistan.
Sara Zahid
Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Pakistan.
Sampath Chinnam
Department of Chemistry, M.S. Ramaiah Institute of Technology, Bengaluru, Karnataka, 560054, India.
Ayesha Zubair
Department of Biochemistry, CMH Lahore Medical College and Institute of Dentistry. National University of Medical Sciences (NUMS), Islamabad.
Fahad Sarfraz
Medical Education Department, School of Health Professions Education, CMH Lahore Medical College and Institute of Dentistry, National University of Medical Sciences (NUMS), Islamabad.
Maria Shah
Department of Pharmacy, University of Swabi, KPK.
Umair Ilyas
Riphah International University, Islamabad, Pakistan.
Rubia Anwer
Ibadat International University (IIUI), Islamabad, Pakistan.
Zeeshan Akbar
Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Arshad Ali Shah
Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Shahzad Anwar
School of Pain and Regenerative Medicine, The University of Lahore, Lahore, Pakistan.
Arif Malik
School of Pain and Regenerative Medicine, The University of Lahore, Lahore, Pakistan.